Boehringer organizes a coalition in search of first CF gene therapy, working with research, manufacturing partners
Joining hands with several academic and industry partners from the UK, Boehringer Ingelheim is launching a quest to develop a gene therapy for cystic fibrosis — one that, if successful, would shake up a field plagued by some recent failures and dominated by Vertex.
The backbone of the collaboration is 17 years worth of work done by the UK Cystic Fibrosis Gene Therapy Consortium, pulling together researchers from Imperial College London and the Universities of Oxford and Edinburgh. With help from Boehringer, the consortium will lead the development and completion of preclinical studies on a gene therapy that it’s identified, to a point where the product will be ready for human studies.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.